Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALXO ALX Oncology	$1.17 +13.6%	$0.57	$0.40 ▼ $2.59	$55.16M	1.14	1.60 million shs	2.86 million shs
ANVS Annovis Bio	$2.38 +0.1%	$2.62	$1.11 ▼ $10.54	$46.18M	1.51	262,847 shs	346,257 shs
AVTE Aerovate Therapeutics	$8.23 +11.5%	$8.67	$56.35 ▼ $105.00	$238.55M	0.95	12,438 shs	124,811 shs
CTNM Contineum Therapeutics	$9.94 -1.0%	$5.39	$3.35 ▼ $20.55	$281.54M	1.04	206,175 shs	214,010 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALXO ALX Oncology	+13.59%	+81.59%	+131.13%	+152.32%	-53.20%
ANVS Annovis Bio	+0.08%	-12.75%	-9.60%	+19.70%	-75.21%
AVTE Aerovate Therapeutics	+0.27%	+9.01%	-17.82%	+4.98%	-88.78%
CTNM Contineum Therapeutics	-1.00%	+34.69%	+80.73%	+178.43%	-46.27%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALXO ALX Oncology	3.0691 of 5 stars	3.4	1.0	0.0	0.0	1.9	4.2	1.3
ANVS Annovis Bio	2.5185 of 5 stars	3.3	3.0	0.0	0.0	2.1	1.7	0.6
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CTNM Contineum Therapeutics	3.323 of 5 stars	3.6	5.0	0.0	0.0	3.1	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALXO ALX Oncology	2.83	Moderate Buy	$3.30	182.05% Upside
ANVS Annovis Bio	2.60	Moderate Buy	$18.00	655.67% Upside
AVTE Aerovate Therapeutics	0.00	N/A	N/A	N/A
CTNM Contineum Therapeutics	3.17	Buy	$22.75	128.87% Upside

Current Analyst Ratings Breakdown

Latest ANVS, ALXO, AVTE, and CTNM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	CTNM Contineum Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$20.00 ➝ $21.00
8/8/2025	ANVS Annovis Bio	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/20/2025	CTNM Contineum Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
6/9/2025	ANVS Annovis Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $12.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALXO ALX Oncology	N/A	N/A	N/A	N/A	$1.20 per share	N/A
ANVS Annovis Bio	N/A	N/A	N/A	N/A	$0.94 per share	N/A
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	$3.96 per share	N/A
CTNM Contineum Therapeutics	$50M	5.57	N/A	N/A	$6.11 per share	1.63

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALXO ALX Oncology	-$134.85M	-$2.20	N/A	N/A	N/A	N/A	-115.67%	-84.82%	11/6/2025 (Estimated)
ANVS Annovis Bio	-$24.59M	-$2.04	N/A	N/A	N/A	N/A	-206.01%	-158.26%	N/A
AVTE Aerovate Therapeutics	-$75.52M	-$1.70	N/A	N/A	N/A	N/A	-90.19%	-77.47%	11/10/2025 (Estimated)
CTNM Contineum Therapeutics	-$42.26M	-$2.20	N/A	N/A	N/A	N/A	-29.75%	-28.08%	11/5/2025 (Estimated)

Latest ANVS, ALXO, AVTE, and CTNM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	ALXO ALX Oncology	-$0.46	-$0.49	-$0.03	-$0.49	N/A	N/A
8/12/2025	Q2 2025	ANVS Annovis Bio	-$0.36	-$0.32	+$0.04	-$0.32	N/A	N/A
8/5/2025	Q2 2025	CTNM Contineum Therapeutics	-$0.56	-$0.62	-$0.06	-$0.62	$7.50 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALXO ALX Oncology	N/A	N/A	N/A	N/A	N/A
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
AVTE Aerovate Therapeutics	N/A	N/A	N/A	N/A	N/A
CTNM Contineum Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALXO ALX Oncology	0.11	4.52	4.52
ANVS Annovis Bio	N/A	7.65	7.65
AVTE Aerovate Therapeutics	N/A	8.78	8.78
CTNM Contineum Therapeutics	N/A	24.51	24.51

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALXO ALX Oncology	97.97%
ANVS Annovis Bio	15.83%
AVTE Aerovate Therapeutics	N/A
CTNM Contineum Therapeutics	N/A

Insider Ownership

Company	Insider Ownership
ALXO ALX Oncology	21.00%
ANVS Annovis Bio	20.80%
AVTE Aerovate Therapeutics	24.90%
CTNM Contineum Therapeutics	11.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALXO ALX Oncology	40	53.55 million	42.31 million	Optionable
ANVS Annovis Bio	3	19.49 million	15.43 million	Optionable
AVTE Aerovate Therapeutics	20	28.99 million	21.69 million	Optionable
CTNM Contineum Therapeutics	31	28.04 million	24.87 million	N/A

ANVS, ALXO, AVTE, and CTNM Headlines

Recent News About These Companies

Contineum Therapeutics, Inc. (NASDAQ:CTNM) Short Interest Update

August 21 at 4:47 AM | marketbeat.com

Positive week for Contineum Therapeutics, Inc. (NASDAQ:CTNM) institutional investors who lost 47% over the past year

August 20 at 5:39 PM | finance.yahoo.com

Contineum Therapeutics (NASDAQ:CTNM) Stock Price Expected to Rise, Morgan Stanley Analyst Says

August 20 at 9:24 AM | marketbeat.com

Morgan Stanley Boosts Contineum Therapeutics (NASDAQ:CTNM) Price Target to $21.00

August 20 at 2:47 AM | americanbankingnews.com

Analysts Offer Insights on NA Companies: Contineum Therapeutics, Inc. Class A (CTNM) and BrightSpring Health Services, Inc. (BTSG)

August 17, 2025 | theglobeandmail.com

Contineum Therapeutics Reports Q2 2025 Results and Clinical Progress

August 13, 2025 | tipranks.com

Contineum Therapeutics, Inc. (NASDAQ:CTNM) Receives $22.50 Average PT from Analysts

August 12, 2025 | americanbankingnews.com

Contineum Therapeutics (NASDAQ:CTNM) Shares Down 3.9% - Time to Sell?

August 10, 2025 | marketbeat.com

Contineum Therapeutics, Inc. (NASDAQ:CTNM) Given Consensus Recommendation of "Buy" by Brokerages

August 10, 2025 | marketbeat.com

William Blair Has Bullish Forecast for CTNM Q3 Earnings

August 9, 2025 | marketbeat.com

Wall Street Analysts Think Contineum Therapeutics, Inc. (CTNM) Could Surge 235.81%: Read This Before Placing a Bet

August 8, 2025 | zacks.com

Contineum Therapeutics (NASDAQ:CTNM) Issues Earnings Results, Misses Expectations By $0.06 EPS

August 6, 2025 | marketbeat.com

Contineum Therapeutics (CTNM) Projected to Post Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

Contineum (CTNM) Q2 R&D Jumps 78%

August 5, 2025 | fool.com

Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones

August 5, 2025 | businesswire.com

Contineum Therapeutics Inc. (CTNM) Stock Price Today - WSJ

August 1, 2025 | wsj.com

Contineum Therapeutics stock falls after trial data delay

June 25, 2025 | investing.com

Contineum Therapeutics Shares Drop After Delay in Trial Data Release

June 25, 2025 | msn.com

Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791

June 25, 2025 | businesswire.com

Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference

May 15, 2025 | businesswire.com

Contineum Therapeutics Reports Q1 2025 Financial Results

May 14, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANVS, ALXO, AVTE, and CTNM Company Descriptions

ALX Oncology NASDAQ:ALXO

$1.17 +0.14 (+13.59%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.16 0.00 (-0.43%)

As of 08/22/2025 07:57 PM Eastern

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma. It also has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under Phase 1 trial for the treatment of breast cancer and other solid tumors; Quantum Leap Healthcare collaborative with an ADC, fam-trastuzumab deruxtecan-nxki, under Phase 1 trial for the treatment of patients with breast cancer; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; Sanofi with isatuximab and dexamethasone, under Phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma; Academic Gastrointestinal Cancer Consortium with pembrolizumab and cetuximab, under Phase 2 trial to treat refractory microsatellite stable metastatic colorectal cancer; and University of Pittsburgh with liposomal doxorubicin and pembrolizumab, under Phase 2 trial recurrent platinum-resistant ovarian cancer. In addition, the company has collaboration agreement with Tallac Therapeutics, Inc. for the development of ALTA-002, a potent immune activator targeted to myeloid cells in the tumor to promote innate and adaptive anti-cancer immune responses. It also has license agreements with Board of Trustees of the Leland Stanford Junior University, Selexis SA, and Crystal Bioscience, Inc. The company was incorporated in 2015 and is headquartered in South San Francisco, California.

Annovis Bio NYSE:ANVS

$2.38 +0.00 (+0.08%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$2.38 0.00 (-0.08%)

As of 08/22/2025 07:58 PM Eastern

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Aerovate Therapeutics NASDAQ:AVTE

$8.23 +0.85 (+11.52%)

As of 08/22/2025

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Contineum Therapeutics NASDAQ:CTNM

$9.94 -0.10 (-1.00%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$9.46 -0.48 (-4.83%)

As of 08/22/2025 07:59 PM Eastern

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time